Ovid Therapeutics Inc
NASDAQ:OVID
Intrinsic Value
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. [ Read More ]
The intrinsic value of one OVID stock under the Base Case scenario is 2.58 USD. Compared to the current market price of 2.99 USD, Ovid Therapeutics Inc is Overvalued by 14%.
Valuation Backtest
Ovid Therapeutics Inc
Run backtest to discover the historical profit from buying and selling OVID stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Ovid Therapeutics Inc
Current Assets | 109.6m |
Cash & Short-Term Investments | 105.8m |
Other Current Assets | 3.8m |
Non-Current Assets | 34.4m |
Long-Term Investments | 17.6m |
PP&E | 14.7m |
Intangibles | 183k |
Other Non-Current Assets | 2m |
Current Liabilities | 11.5m |
Accounts Payable | 3.7m |
Accrued Liabilities | 7.8m |
Non-Current Liabilities | 44.8m |
Other Non-Current Liabilities | 44.8m |
Earnings Waterfall
Ovid Therapeutics Inc
Revenue
|
391.7k
USD
|
Operating Expenses
|
-59.7m
USD
|
Operating Income
|
-59.3m
USD
|
Other Expenses
|
6.9m
USD
|
Net Income
|
-52.3m
USD
|
Free Cash Flow Analysis
Ovid Therapeutics Inc
OVID Profitability Score
Profitability Due Diligence
Ovid Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Ovid Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
OVID Solvency Score
Solvency Due Diligence
Ovid Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Ovid Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OVID Price Targets Summary
Ovid Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for OVID is 7.48 USD with a low forecast of 4.04 USD and a high forecast of 11.55 USD.
Ownership
OVID Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
OVID Price
Ovid Therapeutics Inc
Average Annual Return | 16.93% |
Standard Deviation of Annual Returns | 73.95% |
Max Drawdown | -83% |
Market Capitalization | 211.4m USD |
Shares Outstanding | 70 710 000 |
Percentage of Shares Shorted | 4.84% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 44 full-time employees. The company went IPO on 2017-05-05. The firm is focused on developing medicines for patients and families living with epilepsies, seizure-related disorders and neurological disorders. The Company’s programs include OV329 (GABA aminotransferase inhibitor), OV350, OV882, and OV815 and OV825. OV329 (GABA aminotransferase inhibitor) is a next-generation GABA aminotransferase inhibitor being developed for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms. OV329 functions by substantially reducing the activity of GABA aminotransferase (GABA-AT), a key enzyme responsible for the degradation of the brain’s major inhibitory neurotransmitter, GABA. OV350 is a small molecule that directly activates the KCC2 transporter, which is an important channel in seizure control. OV882, which is a short hairpin RNA (shRNA-551) for Angelman syndrome. OV815, which is a genetic therapy approach for KIF1A-associated neurological disorders.
Contact
IPO
Employees
Officers
The intrinsic value of one OVID stock under the Base Case scenario is 2.58 USD.
Compared to the current market price of 2.99 USD, Ovid Therapeutics Inc is Overvalued by 14%.